文献速递糖尿病

2型糖尿病患者对钠-葡萄糖协同转运蛋白2抑制的酮体肾脏处理反应

Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2017-03-21

研究在66例肾功能保留的2型糖尿病患者及无糖尿病对照中,测量空腹及餐后尿糖、β-羟丁酸、乳酸和钠的排泄,并在恩格列净治疗4周后复测。结果示慢性SGLT2抑制使尿糖排泄分数从基线<2%升至空腹38±12%、餐后46±11%,β-羟丁酸、乳酸和钠排泄均增加且与尿糖正相关。结论认为SGLT2抑制剂所致β-羟丁酸升高源于生成过多而非肾脏清除减少。

要点

  • 慢性SGLT2抑制4周后,尿糖排泄分数从基线<2%升至空腹38±12%、餐后46±11%(P<0.0001)。
  • β-羟丁酸、乳酸和钠排泄均增加(P≤0.001),且各自与尿糖排泄正相关(P≤0.001)。
  • 血浆促红细胞生成素浓度增加31(64)%(P=0.0078),而N末端B型利钠肽原水平未改变。

核心结论

  • SGLT2抑制剂引起的β-羟丁酸升高不是由于肾脏清除减少,而是由于生成过多。
  • 乳酸排泄增加有助于降低血浆乳酸水平,而钠排泄增加可能有助于使可交换钠池正常化。
  • 近端小管联合抑制葡萄糖和钠重吸收所致的葡萄糖丢失引起肾脏代谢的多重改变。

研究设计与样本

  • 研究纳入66例既往已报告的2型糖尿病患者(估算肾小球滤过率≥60 mL·min-1·1.73m-2,肾功能保留)及无糖尿病对照受试者。
  • 在基线及恩格列净治疗4周后,测量空腹和餐后尿液中葡萄糖、β-羟丁酸、乳酸和钠的排泄。

主要发现

  • 慢性(4周)SGLT2抑制后,基线尿糖排泄分数(<2%)升至空腹38±12%和餐后46±11%(空腹vs餐后,P<0.0001),覆盖BMI范围23-41 kg/m2及肌酐清除率65-168 mL·min-1·m-2。
  • β-羟丁酸排泄从0.08(0.10)增至0.31(0.43)µmol·min-1,乳酸从0.06(0.06)增至0.28(0.25)µmol·min-1,钠从0.27(0.22)增至0.36(0.16)mEq·min-1,均增加(P≤0.001),且各自与尿糖排泄正相关(P≤0.001)。
  • 无糖尿病受试者中这些参数变化方向相同,但变化幅度小于2型糖尿病患者。
  • 血浆N末端B型利钠肽原水平未改变,而血浆促红细胞生成素浓度增加31(64)%(P=0.0078)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pharmacologically induced glycosuria elicits adaptive responses in glucose homeostasis and hormone release, including decrements in plasma glucose and insulin levels, increments in glucagon release, enhanced lipolysis, and stimulation of ketogenesis, resulting in an increase in ketonemia. We aimed at assessing the renal response to these changes. RESEARCH DESIGN AND METHODS: We measured fasting and postmeal urinary excretion of glucose, β-hydroxybutyrate (β-HB), lactate, and sodium in 66 previously reported patients with type 2 diabetes and preserved renal function (estimated glomerular filtration rate ≥60 mL · min-1 · 1.73 m-2) and in control subjects without diabetes at baseline and following empagliflozin treatment. RESULTS: With chronic (4 weeks) sodium-glucose cotransporter 2 inhibition, baseline fractional glucose excretion (<2%) rose to 38 ± 12% and 46 ± 11% (fasting vs. postmeal, respectively; P < 0.0001) over a range of BMIs (range 23-41 kg/m2) and creatinine clearance (65-168 mL · min-1 · m-2). Excretion of β-HB (median [interquartile range]: 0.08 [0.10] to 0.31 [0.43] µmol · min-1), lactate (0.06 [0.06] to 0.28 [0.25] µmol · min-1), and sodium (0.27 [0.22] to 0.36 [0.16] mEq · min-1) all increased (P ≤ 0.001 for all) and were each positively related to glycosuria (P ≤ 0.001). These parameters changed in the same direction in subjects without diabetes, but changes were smaller than in the patients with diabetes. Although plasma N-terminal pro-B-type natriuretic peptide levels were unaltered, plasma erythropoietin concentrations increased by 31 (64)% (P = 0.0078). CONCLUSIONS: We conclude that the sodium-glucose cotransporter 2 inhibitor-induced increase in β-HB is not because of reduced renal clearance but because of overproduction. The increased lactate excretion contributes to lower plasma lactate levels, whereas the increased natriuresis may help in normalizing the exchangeable sodium pool. Taken together, glucose loss through joint inhibition of glucose and sodium reabsorption in the proximal tubule induces multiple changes in renal metabolism.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ferrannini E, Baldi S, Frascerra S, et al. Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care. 2017. PMID: 28325783. doi:10.2337/dc16-2724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。